Sensorium Therapeutics Inc. has synthesized mesembrine derivatives acting as serotonin transporter (SERT) inhibitors reported to be useful for the treatment of anxiety, depression and stress disorders.
The first patenting from Neuro-Joy Ltd. details development of a device that electrically stimulates facial nerves and muscles in order to emulate a facial expression configured to ameliorate a mood disorder and improve symptoms of depression, anxiety and sleep disorders.
Targeting NMDA in mental health has chalked wins but not universally, as shown by Sage Therapeutics Inc.’s failure of the placebo-controlled phase II Lightwave study testing dalzanemdor in Alzheimer's disease, which missed the primary outcome measure, another bit of bad luck from the company that was disclosed Oct. 8.
In what represents the first patenting from Cerathrive Ltd., its co-founder and CEO, Sarah Turner, describes their development of the Cera system, which they claim to be the first and only U.S. FDA-cleared red-light device that targets the gut-brain axis to improve focus and energy levels.
Mental tech startup Doctorpresso Co. Ltd. launched an audio journaling mobile application called Redi, in South Korea, as a voice analysis software capable of detecting depression through artificial intelligence-aided speech analysis.
Otsuka Precision Health Inc. and Click Therapeutics Inc. pondered the signature question of cognitive behavioral therapy when setting the market approach for their jointly developed prescription digital therapeutic for major depressive disorder, Rejoyn.
Mira Pharmaceuticals Inc. has released new preclinical study results for its oral ketamine analogue, Ketamir-2, which is under investigation for potential to treat neurological and neuropsychiatric disorders, including depression, treatment-resistant depression and post-traumatic stress disorder.
Korea Institute of Science and Technology has described diosgenin derivatives reported to be useful for the treatment of depression, multiple sclerosis, ischemic stroke, schizophrenia, amyotrophic lateral sclerosis, neuroblastoma, Alzheimer’s disease and post-traumatic stress disorders.
Entheogenix Biosciences Inc. has described 5-HT2A receptor agonists reported to be useful for the treatment of post-traumatic stress, depression and anxiety disorders.
Scientists at Shanghai Institute of Materia Medica of the Chinese Academy of Sciences, Suzhou Vigonvita Life Sciences Co. Ltd. and The Xinjiang Technical Institute of Physics & Chemistry of the Chinese Academy of Sciences have disclosed NMDA receptor antagonists reported to be useful for the treatment of neurological disorders.
